https://www.pharmaradar360.com/article/partnership-to-create-ai-chemical-data-ecosystem-057e7a3c68334cd4Pharma Surgeen2026-08-03T10:18:40.000ZPartnership to create AI chemical data ecosystemhttps://www.pharmaradar360.com/article/varda-announces-biopharma-leader-mikael-dolsten-will-join-board-as-space-based-p-e4fb549a68f2d79cPharma Surgeen2026-08-03T10:00:00.000ZVarda Announces Biopharma Leader Mikael Dolsten will Join Board as Space-Based Pharmaceutical Manufacturing Accelerateshttps://www.pharmaradar360.com/article/this-next-gen-glp-1-is-blowing-up-the-black-market-economy-789b37562a6bdc5aPharma Surgeen2026-08-03T10:00:00.000ZThis Next-Gen GLP-1 Is Blowing Up the Black Market Economyhttps://www.pharmaradar360.com/article/south-africa-prepares-for-potential-new-adult-tb-vaccine-13e0094d65226d45Pharma Surgeen2026-08-03T09:54:26.000ZSouth Africa Prepares for Potential New Adult TB Vaccinehttps://www.pharmaradar360.com/article/jeol-launches-two-high-resolution-microscopes-14fa5a388e190348Pharma Surgeen2026-08-03T09:48:03.000ZJeol launches two high-resolution microscopeshttps://www.pharmaradar360.com/article/radiopharm-asx-rad-expands-clinical-momentum-with-positive-trial-updates-80d2bdd2128ddf12Pharma Surgeen2026-08-03T09:47:00.000ZRadiopharm (ASX:RAD) Expands Clinical Momentum with Positive Trial Updateshttps://www.pharmaradar360.com/article/what-will-health-and-social-care-look-like-under-andy-burnham-dba84f191db4b195Pharma Surgeen2026-08-03T09:42:17.000ZWhat will health and social care look like under Andy Burnham?https://www.pharmaradar360.com/article/impact-licenses-ovarian-cancer-drug-senaparib-to-pharmanovia-cdc5924972d68a16Pharma Surgeen2026-08-03T09:00:51.000ZIMPACT licenses ovarian cancer drug senaparib to Pharmanoviahttps://www.pharmaradar360.com/article/unlocking-peptide-permeability-with-high-throughput-sfc-epsa-analysis-eb2c8abc5f6e24c6Pharma Surgeen2026-08-03T08:54:43.000ZUnlocking peptide permeability with high-throughput SFC-EPSA analysishttps://www.pharmaradar360.com/article/breast-cancer-trial-highlights-promise-and-risks-of-dual-immunotherapy-61f474a8f3b39983Pharma Surgeen2026-08-03T08:54:24.000ZBreast Cancer Trial Highlights Promise and Risks of Dual Immunotherapyhttps://www.pharmaradar360.com/article/sven-borho-steps-down-from-worldwide-health-with-biotech-growth-s-hsu-becoming-c-cfa958a4e77a26b7Pharma Surgeen2026-08-03T08:48:04.000ZSven Borho steps down from Worldwide Health with Biotech Growth's Hsu becoming co-managerhttps://www.pharmaradar360.com/article/astrazeneca-and-bms-in-talks-over-major-pharmaceutical-merger-9bba81a2f5976adePharma Surgeen2026-08-03T08:47:52.000ZAstraZeneca And BMS In Talks Over Major Pharmaceutical Mergerhttps://www.pharmaradar360.com/article/regulatory-round-up-3-august-2026-317fac41e47f8f05Pharma Surgeen2026-08-03T08:45:47.000ZRegulatory round-up: 3 August 2026https://www.pharmaradar360.com/article/astrazeneca-in-talks-to-create-300bn-pharmaceutical-giant-f730c2e4f3a0c6bePharma Surgeen2026-08-03T08:36:00.000ZAstraZeneca ‘in talks to create £300bn pharmaceutical giant’https://www.pharmaradar360.com/article/dongkook-pharm-nears-w1-trillion-sales-milestone-83545cfd7cd251cbPharma Surgeen2026-08-03T08:30:43.000ZDongkook Pharm Nears W1 Trillion Sales Milestonehttps://www.pharmaradar360.com/article/pneumococcal-polysaccharide-conjugate-vaccine-pcv20-pgd-template-e123e687bede1c8dPharma Surgeen2026-08-03T08:30:00.000ZPneumococcal polysaccharide conjugate vaccine (PCV20) PGD templatehttps://www.pharmaradar360.com/article/pcv-13-valent-or-15-valent-adsorbed-patient-group-direction-pgd-template-9f8a91512dbcc4ffPharma Surgeen2026-08-03T08:30:00.000ZPCV (13-valent or 15-valent, adsorbed): patient group direction (PGD) templatehttps://www.pharmaradar360.com/article/dhsc-privacy-notice-6199fbf5d25ab84cPharma Surgeen2026-08-03T08:30:00.000ZDHSC privacy noticehttps://www.pharmaradar360.com/article/department-of-health-and-social-care-record-of-processing-activity-ropa-0a8251143f475789Pharma Surgeen2026-08-03T08:30:00.000ZDepartment of Health and Social Care record of processing activity (RoPA)https://www.pharmaradar360.com/article/bcg-vaccine-ajv-patient-group-direction-pgd-template-d5eac209b6d2a75cPharma Surgeen2026-08-03T08:30:00.000ZBCG Vaccine AJV: patient group direction (PGD) templatehttps://www.pharmaradar360.com/article/billionaire-stanley-druckenmiller-bought-this-biotech-stock-that-has-surged-400-3e0951d9f0d4c95fPharma Surgeen2026-08-03T08:15:02.000ZBillionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?https://www.pharmaradar360.com/article/billionaire-stanley-druckenmiller-bought-this-biotech-stock-that-has-surged-400-dcbf1871be4923ebPharma Surgeen2026-08-03T08:12:00.000ZBillionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?https://www.pharmaradar360.com/article/south-africa-prepares-for-potential-breakthrough-adult-tb-vaccine-955197d00a68213fPharma Surgeen2026-08-03T07:52:27.000ZSouth Africa prepares for potential breakthrough adult TB vaccinehttps://www.pharmaradar360.com/article/media-astrazeneca-and-bristol-myers-hold-mega-merger-talks-d044c268337764d7Pharma Surgeen2026-08-03T07:48:54.000ZMedia: AstraZeneca and Bristol Myers hold mega-merger talkshttps://www.pharmaradar360.com/article/one-of-china-s-major-pharmaceutical-companies-joined-belarusian-stock-market-613188fcb9d89fdfPharma Surgeen2026-08-03T07:41:00.000ZOne of China’s major pharmaceutical companies joined Belarusian stock markethttps://www.pharmaradar360.com/article/dr-ram-sarma-joins-virchow-biotech-as-chief-operating-officer-bb17614545bc2ac2Pharma Surgeen2026-08-03T07:33:24.000ZDr. Ram Sarma Joins Virchow Biotech as Chief Operating Officerhttps://www.pharmaradar360.com/article/zeus-delivers-a-bolt-of-pain-to-novo-nordisk-25373ee3560d6041Pharma Surgeen2026-08-03T07:26:02.000ZZEUS delivers a bolt of pain to Novo Nordiskhttps://www.pharmaradar360.com/article/moleculin-biotech-reports-positive-pivotal-phase-2-3-trial-results-for-annamycin-74d085c35cffa9c8Pharma Surgeen2026-08-03T07:19:06.000ZMoleculin Biotech Reports Positive Pivotal Phase 2/3 Trial Results for Annamycin in AMLhttps://www.pharmaradar360.com/article/astrazeneca-bristol-myers-squibb-discuss-mega-merger-73beab93d51c0a25Pharma Surgeen2026-08-03T07:15:52.000ZAstraZeneca, Bristol Myers Squibb Discuss Mega-Mergerhttps://www.pharmaradar360.com/article/investor-lawsuit-looms-lawyer-predicts-three-consequences-for-novo-nordisk-255f39fb9c951eb1Pharma Surgeen2026-08-03T07:09:00.000ZInvestor lawsuit looms: Lawyer predicts three consequences for Novo Nordiskhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-amundi-f289585d0a1f2be8Pharma Surgeen2026-08-03T07:06:48.000ZTeva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Amundihttps://www.pharmaradar360.com/article/montana-s-new-right-to-try-opening-the-door-to-profit-from-unproven-drugs-ca59a447334f0593Pharma Surgeen2026-08-03T07:02:58.000ZMontana’s new “right to try”: Opening the door to profit from unproven drugshttps://www.pharmaradar360.com/article/fda-approves-long-lasting-otc-pain-reliever-combining-acetaminophen-and-naproxen-b705877d8a45bc85Pharma Surgeen2026-08-03T07:00:50.000ZFDA approves long-lasting OTC pain reliever combining acetaminophen and naproxenhttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-shares-fall-2-in-early-trade-3b6dc738ffec22acPharma Surgeen2026-08-03T06:54:10.000ZSun Pharmaceutical Industries shares fall 2% in early tradehttps://www.pharmaradar360.com/article/mesoblast-s-ryoncil-posts-115m-first-year-revenue-on-pediatric-approval-e38c06a60eb4da14Pharma Surgeen2026-08-03T06:38:08.000ZMesoblast’s Ryoncil Posts $115M First-Year Revenue on Pediatric Approvalhttps://www.pharmaradar360.com/article/fda-advisory-no-2026-0861-public-health-warning-against-the-purchase-and-use-of-aa6977e3d44274f9Pharma Surgeen2026-08-03T06:36:29.000ZFDA Advisory No.2026-0861 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Tsunami® Plant Essence Herbal Recipe 15 g”https://www.pharmaradar360.com/article/what-is-retatrutide-for-weight-loss-view-caaqswt8m-76220cded81dc1baPharma Surgeen2026-08-03T06:23:51.000ZWhat Is Retatrutide for Weight Loss? - View CAAQswt8mhttps://www.pharmaradar360.com/article/dr-reddy-s-rituximab-biosimilar-gets-approval-from-us-fda-b6a018bb37c23738Pharma Surgeen2026-08-03T06:22:07.000ZDr. Reddy's Rituximab biosimilar gets approval from US FDAhttps://www.pharmaradar360.com/article/concord-biotech-consolidated-profit-rises-43-7-in-q1fy26-249d19d0d23826bePharma Surgeen2026-08-03T06:15:57.000ZConcord Biotech consolidated profit rises 43.7% in Q1FY26https://www.pharmaradar360.com/article/alto-neuroscience-buy-alto-207-advancement-trd-and-other-expansion-indications-a-ed88996de6106136Pharma Surgeen2026-08-03T06:04:17.000ZAlto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications (ANRO)https://www.pharmaradar360.com/article/la-aemps-colabora-con-la-agencia-reguladora-de-ghana-para-fortalecer-sus-capacid-00b1e41c4a61a1cePharma Surgeen2026-08-03T06:00:08.000ZLa AEMPS colabora con la agencia reguladora de Ghana para fortalecer sus capacidades para la evaluación de medicamentos biológicoshttps://www.pharmaradar360.com/article/weight-loss-research-news-view-t4ylvlml1-b24227777c7877cbPharma Surgeen2026-08-03T05:35:17.000ZWeight Loss Research News - View t4yLvLml1https://www.pharmaradar360.com/article/is-stronger-q2-results-raised-outlook-and-buybacks-altering-the-investment-case-75b7be52c3122d6bPharma Surgeen2026-08-03T05:08:42.000ZIs Stronger Q2 Results, Raised Outlook and Buybacks Altering The Investment Case For West Pharmaceutical Services (WST)?https://www.pharmaradar360.com/article/gas-crisis-strikes-paracetamol-api-other-industries-03fc12f35536dfe1Pharma Surgeen2026-08-03T05:08:39.000ZGas crisis strikes paracetamol API, other industrieshttps://www.pharmaradar360.com/article/mumbai-rusted-metal-pin-allegedly-found-in-kaju-katli-bought-from-charni-roads-t-3fe4f7bfe72bb750Pharma Surgeen2026-08-03T05:08:17.000ZMumbai: Rusted Metal Pin Allegedly Found In Kaju Katli Bought From Charni Roads Tewari Bros Sweet Shop; Videohttps://www.pharmaradar360.com/article/viking-therapeutics-bionxt-solutions-and-bausch-health-clinical-success-sparks-f-00a525e6ed74d761Pharma Surgeen2026-08-03T05:07:46.000ZViking Therapeutics, BioNxt Solutions, and Bausch Health: Clinical Success Sparks Fresh Optimismhttps://www.pharmaradar360.com/article/botanix-pharmaceuticals-asx-bot-jumps-5-per-cent-on-a-single-tick-not-a-biotech-600ec24db9193bdePharma Surgeen2026-08-03T05:04:00.000ZBotanix Pharmaceuticals (ASX:BOT) – Jumps 5 Per Cent on a Single Tick, Not a Biotech Revivalhttps://www.pharmaradar360.com/article/can-irbesartan-cause-erectile-dysfunction-view-wnckv3rkn-71ec5e46213c4f03Pharma Surgeen2026-08-03T04:47:11.000ZCan Irbesartan Cause Erectile Dysfunction - View WnCkv3RKNhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-raised-guidance-is-the-upside-already-priced-in-7f982eece2cabac7Pharma Surgeen2026-08-03T04:32:00.000ZWest Pharmaceutical Services (WST) Raised Guidance, Is The Upside Already Priced In?https://www.pharmaradar360.com/article/kelun-biotech-receives-china-clearance-to-begin-clinical-development-of-dual-pay-807d665e6674bd69Pharma Surgeen2026-08-03T04:12:58.000ZKelun-Biotech receives China clearance to begin clinical development of dual-payload ADChttps://www.pharmaradar360.com/article/biotech-leaders-call-for-streamlining-of-inds-as-fda-s-trialblazer-rolls-out-3b83311b2a27e73fPharma Surgeen2026-08-03T04:10:57.000ZBiotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls outhttps://www.pharmaradar360.com/article/5-companies-advancing-attr-assets-in-the-wake-of-wainua-s-fail-5f3e3d297990ff59Pharma Surgeen2026-08-03T04:10:57.000Z5 companies advancing ATTR assets in the wake of Wainua’s failhttps://www.pharmaradar360.com/article/texas-pickleball-is-blazing-hot-while-california-trim-clinic-says-peptides-are-t-c7433cbc0da72c91Pharma Surgeen2026-08-03T04:10:23.000ZTexas Pickleball Is Blazing Hot, While California Trim Clinic Says Peptides Are Turning Up the Heathttps://www.pharmaradar360.com/article/astrazeneca-bristol-myers-squibb-in-merger-talks-to-create-nearly-400-billion-ph-1b5457d3b64574ecPharma Surgeen2026-08-03T03:57:07.000ZAstraZeneca, Bristol Myers Squibb in Merger Talks to Create Nearly $400 Billion Pharma Gianthttps://www.pharmaradar360.com/article/how-china-s-innovative-pharmaceutical-industry-accelerates-with-reform-745e94de9c989340Pharma Surgeen2026-08-03T03:34:13.000ZHow China's innovative pharmaceutical industry accelerates with reformhttps://www.pharmaradar360.com/article/piramal-pharmas-quarterly-results-reflect-resilience-in-the-pharmaceutical-indus-d4b4fac3245a156bPharma Surgeen2026-08-03T03:11:28.000ZPiramal Pharmas Quarterly Results Reflect Resilience in the Pharmaceutical Industryhttps://www.pharmaradar360.com/article/shinsa-information-on-biosimilars-is-updated-4166254cb4a37a8aPharma Surgeen2026-08-03T03:00:00.000Z[SHINSA]Information on biosimilars is updatedhttps://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-3e55177ed02846faPharma Surgeen2026-08-03T02:48:00.000ZBiotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?https://www.pharmaradar360.com/article/fauci-hearing-fact-check-part-iii-the-safety-claims-the-money-and-the-question-n-7cfbc937e01d2f6bPharma Surgeen2026-08-03T02:44:21.000ZFauci hearing fact-check - Part III - the safety claims, the money, and the question nobody answeredhttps://www.pharmaradar360.com/article/hlb-panagene-signs-exclusive-singapore-pna-supply-deal-with-roche-affiliated-res-b9c6cb4cebe69319Pharma Surgeen2026-08-03T02:25:00.000ZHLB Panagene Signs Exclusive Singapore PNA Supply Deal With Roche-Affiliated Research Institutehttps://www.pharmaradar360.com/article/cj-olive-young-expands-advanced-derma-line-with-pharmaceutical-partners-6a75e11b593eb6daPharma Surgeen2026-08-03T02:10:45.000ZCJ Olive Young expands 'Advanced Derma' line with pharmaceutical partnershttps://www.pharmaradar360.com/article/novo-nordisk-s-failed-heart-drug-trial-raises-the-stakes-for-wednesday-s-earning-b907360b5034137dPharma Surgeen2026-08-03T02:02:24.000ZNovo Nordisk's Failed Heart Drug Trial Raises the Stakes for Wednesday's Earningshttps://www.pharmaradar360.com/article/pharmac-to-refresh-patient-advisory-function-c55da6f2b5960b4cPharma Surgeen2026-08-03T02:00:00.000ZPharmac to refresh patient advisory functionhttps://www.pharmaradar360.com/article/ono-pharmaceutical-fy2026-q1-earnings-call-core-operating-profit-up-22-5-to-38-7-7d71b1a12d5a82d0Pharma Surgeen2026-08-03T01:46:00.000Z【Ono Pharmaceutical FY2026 Q1 Earnings Call】Core Operating Profit Up 22.5% to ¥38.7 Billion; Overseas Sales and Royalties Drive Post-Forxiga Revenue Structure, Upside Potential from Weak Yenhttps://www.pharmaradar360.com/article/salmonella-outbreak-tied-to-major-egg-recall-as-nearly-one-hundred-fall-ill-acro-e2f996c895994692Pharma Surgeen2026-08-03T01:38:44.000ZSalmonella Outbreak Tied To Major Egg Recall As Nearly One Hundred Fall Ill Across Seventeen US Stateshttps://www.pharmaradar360.com/article/philippine-consulate-attends-biotech-and-beyond-speaker-series-featuring-thermo-87948c0a498ecd0bPharma Surgeen2026-08-03T01:14:59.000ZPhilippine Consulate Attends Biotech and Beyond Speaker Series Featuring Thermo Fisher Scientifichttps://www.pharmaradar360.com/article/sumitomo-pharma-announces-personnel-change-2fa783b9fbc80194Pharma Surgeen2026-08-03T01:00:00.000ZSumitomo Pharma Announces Personnel Changehttps://www.pharmaradar360.com/article/this-biotech-stock-nearly-doubled-in-value-today-morning-what-s-driving-investor-2b6d85a1f88a0aebPharma Surgeen2026-08-03T00:25:27.000ZThis Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?https://www.pharmaradar360.com/article/sfda-approves-first-daily-oral-weight-loss-drug-for-adults-with-obesity-05dfa119b37f0dc2Pharma Surgeen2026-08-03T00:23:00.000ZSFDA approves first daily oral weight-loss drug for adults with obesityhttps://www.pharmaradar360.com/article/fujifilm-and-taiho-pharmaceutical-enter-into-strategic-partnership-for-developme-d35ba8df72551131Pharma Surgeen2026-08-03T00:00:00.000ZFujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Generation Antibody-Drug Conjugate (ADC) Manufacturing Technologies Optimizing Manufacturing Processes to Enable Stable Production of High-Quality ADCshttps://www.pharmaradar360.com/article/publication-of-sustainability-report-2026-ddc2615ce892b29aPharma Surgeen2026-08-03T00:00:00.000ZPublication of Sustainability Report 2026https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-325f397305d974a1Pharma Surgeen2026-08-03T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-594a38c56dc3919aPharma Surgeen2026-08-03T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-3d751053fc96f00bPharma Surgeen2026-08-03T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-2bca36375a4717baPharma Surgeen2026-08-03T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-21283b5f956edc2cPharma Surgeen2026-08-03T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-50b70b3071fc451aPharma Surgeen2026-08-03T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-3dd86914a7bf7247Pharma Surgeen2026-08-03T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-b20ba48e7eabe3ddPharma Surgeen2026-08-03T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-fd3e20d928ca0167Pharma Surgeen2026-08-03T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-4deeccc6c9da215cPharma Surgeen2026-08-03T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d7794b0dd52bf2caPharma Surgeen2026-08-03T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-1ade2a6b702fa8e9Pharma Surgeen2026-08-03T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-48a2123bd9e68bf7Pharma Surgeen2026-08-03T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-a5a23f8ac9164326Pharma Surgeen2026-08-03T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/national-institute-of-allergy-and-infectious-diseases-notice-of-meeting-c8dc0a63ef1a8f63Pharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Allergy and Infectious Diseases; Notice of Meetinghttps://www.pharmaradar360.com/article/national-institute-of-allergy-and-infectious-diseases-notice-of-meetings-df9179dd51c27d06Pharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Allergy and Infectious Diseases; Notice of Meetingshttps://www.pharmaradar360.com/article/medicare-program-fy-2027-hospice-wage-index-and-payment-rate-update-and-hospice-bef5ad53a04e50b8Pharma Surgeen2026-08-03T00:00:00.000ZMedicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirementshttps://www.pharmaradar360.com/article/national-institute-of-mental-health-notice-of-closed-meeting-082ef3c167dc2b67Pharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Mental Health; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/reducing-bureaucracy-and-burden-in-family-violence-and-prevention-services-417b0a2da45a42d5Pharma Surgeen2026-08-03T00:00:00.000ZReducing Bureaucracy and Burden in Family Violence and Prevention Serviceshttps://www.pharmaradar360.com/article/national-center-for-advancing-translational-sciences-notice-of-meeting-c680d39aeda9a75bPharma Surgeen2026-08-03T00:00:00.000ZNational Center for Advancing Translational Sciences; Notice of Meetinghttps://www.pharmaradar360.com/article/modification-of-certain-terminology-in-title-21-reopening-of-the-comment-period-cb85bc368f0df9a2Pharma Surgeen2026-08-03T00:00:00.000ZModification of Certain Terminology in Title 21; Reopening of the Comment Periodhttps://www.pharmaradar360.com/article/medicare-program-inpatient-rehabilitation-facility-prospective-payment-system-fo-2a384ef76956c3eePharma Surgeen2026-08-03T00:00:00.000ZMedicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2027 and Updates to the IRF Quality Reporting Programhttps://www.pharmaradar360.com/article/current-list-of-hhs-certified-laboratories-and-instrumented-initial-testing-faci-3ca06ee144600e89Pharma Surgeen2026-08-03T00:00:00.000ZCurrent List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencieshttps://www.pharmaradar360.com/article/ricardo-andres-acuna-final-debarment-order-7670ed85c0da5180Pharma Surgeen2026-08-03T00:00:00.000ZRicardo Andres Acuna: Final Debarment Orderhttps://www.pharmaradar360.com/article/angela-anatilde-baquero-final-debarment-order-4031c16e9a33a7eePharma Surgeen2026-08-03T00:00:00.000ZAngela Anatilde Baquero: Final Debarment Orderhttps://www.pharmaradar360.com/article/notice-regarding-340b-rebate-model-pilot-program-d552cd82ac9a888cPharma Surgeen2026-08-03T00:00:00.000ZNotice Regarding 340B Rebate Model Pilot Programhttps://www.pharmaradar360.com/article/biosimilar-and-interchangeable-biosimilar-products-considerations-for-container-02cc0a00e8743596Pharma Surgeen2026-08-03T00:00:00.000ZBiosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts; Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/national-institute-of-nursing-research-notice-of-partially-closed-meeting-8ba45c53db8541f4Pharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Nursing Research; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/national-institute-of-arthritis-and-musculoskeletal-and-skin-diseases-notice-of-0d93c6d075f0d015Pharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-notice-of-partially-closed-m-1f5c5bde6809ff1bPharma Surgeen2026-08-03T00:00:00.000ZNational Institute of Environmental Health Sciences; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/amendment-to-3-4-mdp-2-p-methyl-glycidic-acid-a-list-i-chemical-2a883f1cb312536dPharma Surgeen2026-08-03T00:00:00.000ZAmendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemicalhttps://www.pharmaradar360.com/article/assessing-adhesion-with-transdermal-and-topical-delivery-systems-for-andas-guida-977a29b9dfcaa209Pharma Surgeen2026-08-03T00:00:00.000ZAssessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/assessing-the-irritation-and-sensitization-potential-of-transdermal-and-topical-c1e70688ec00e419Pharma Surgeen2026-08-03T00:00:00.000ZAssessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs; Revised Draft Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-93c3ccc4379e98f8Pharma Surgeen2026-08-03T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; National Health Service Corps Scholar/Students to Service Travel Worksheet, OMB No. 0906-0087-Revisionhttps://www.pharmaradar360.com/article/ai-identifies-previously-unrecognized-health-insights-in-routine-sleep-studies-6f65d9b45d6f11a6Pharma Surgeen2026-08-03T00:00:00.000ZAI Identifies Previously Unrecognized Health Insights in Routine Sleep Studieshttps://www.pharmaradar360.com/article/drug-induced-dysphagia-analysis-of-age-and-time-of-onset-profiles-using-a-japane-2292431fad5a7cd7Pharma Surgeen2026-08-03T00:00:00.000ZDrug-induced dysphagia: Analysis of age and time of onset profiles using a Japanese pharmacovigilance databasehttps://www.pharmaradar360.com/article/screen-time-exposure-sleep-alterations-and-their-relationship-with-excess-weight-cd25e22986fd3b04Pharma Surgeen2026-08-03T00:00:00.000ZScreen time exposure, sleep alterations, and their relationship with excess weight in children and adolescentshttps://www.pharmaradar360.com/article/prevalence-and-clinical-characteristics-of-pediatric-parasitic-gastroenteritis-w-63e844065eb639f7Pharma Surgeen2026-08-03T00:00:00.000ZPrevalence and Clinical Characteristics of Pediatric Parasitic Gastroenteritis with a Comparative Analysis of Diagnostic Methodshttps://www.pharmaradar360.com/article/a-growing-epidemic-of-loneliness-among-us-military-veterans-7edaeca79d55ede2Pharma Surgeen2026-08-03T00:00:00.000ZA Growing Epidemic of Loneliness Among US Military Veteranshttps://www.pharmaradar360.com/article/environmental-and-clinical-spread-of-mdr-acinetobacter-baumannii-a-genomic-epide-4d54f443e5ecfbe9Pharma Surgeen2026-08-03T00:00:00.000ZEnvironmental and Clinical Spread of MDR Acinetobacter baumannii: A Genomic Epidemiology Investigationhttps://www.pharmaradar360.com/article/clinical-utility-of-an-fda-authorized-artificial-intelligence-imaging-platform-i-dc4216fb2b39961ePharma Surgeen2026-08-03T00:00:00.000ZClinical Utility of an FDA-Authorized Artificial Intelligence Imaging Platform in Interstitial Lung Disease Diagnosishttps://www.pharmaradar360.com/article/association-of-intraoperative-cell-salvage-combined-with-standard-allogeneic-tra-af6fce8d0f4708cePharma Surgeen2026-08-03T00:00:00.000ZAssociation of intraoperative cell salvage combined with standard allogeneic transfusion with hematological parameters and clinical outcomes in pediatric tracheoplasty: a non-randomized cohort studyhttps://www.pharmaradar360.com/article/impact-of-evidence-based-nursing-on-clinical-outcomes-in-patients-with-leukemia-3f963159c4a6df49Pharma Surgeen2026-08-03T00:00:00.000ZImpact of evidence-based nursing on clinical outcomes in patients with leukemia undergoing chemotherapyhttps://www.pharmaradar360.com/article/comparison-of-the-efficacy-and-safety-of-nafamostat-mesylate-and-heparin-in-bloo-53f781c94a88cd71Pharma Surgeen2026-08-03T00:00:00.000ZComparison of the efficacy and safety of nafamostat mesylate and heparin in blood purification therapy for patients with severe acute pancreatitis: protocol for a randomized controlled trialhttps://www.pharmaradar360.com/article/molecular-sensitization-profiles-and-parvalbumin-sensitization-burden-associated-4b695003796471e6Pharma Surgeen2026-08-03T00:00:00.000ZMolecular sensitization profiles and β-parvalbumin sensitization burden associated with clinical fish allergy in childrenhttps://www.pharmaradar360.com/article/ultrathin-strut-drug-eluting-stents-are-associated-with-lower-revascularization-0cdf3b55c22531e4Pharma Surgeen2026-08-03T00:00:00.000ZUltrathin-strut drug-eluting stents are associated with lower revascularization rates than drug-coated balloons in non-focal in-stent restenosishttps://www.pharmaradar360.com/article/acute-acalculous-cholecystitis-in-dengue-fever-an-emerging-clinical-entity-87d2a2f80697be0cPharma Surgeen2026-08-03T00:00:00.000ZAcute Acalculous Cholecystitis in Dengue Fever: An Emerging Clinical Entityhttps://www.pharmaradar360.com/article/integration-of-ultrasound-electro-fenton-processes-for-total-organic-carbon-and-7fbf32de80e7787aPharma Surgeen2026-08-03T00:00:00.000ZIntegration of ultrasound-electro-Fenton processes for total organic carbon and inorganic carbon removal in pharmaceutical wastewaterhttps://www.pharmaradar360.com/article/stage-specific-comparative-effectiveness-of-diverting-stoma-as-a-bridge-to-surge-a84db9354ed751a0Pharma Surgeen2026-08-03T00:00:00.000ZStage-Specific Comparative Effectiveness of Diverting Stoma as a Bridge to Surgery Versus Emergency Resection for Obstructive Colorectal Cancer: A Nationwide Target Trial Emulationhttps://www.pharmaradar360.com/article/sonoreasoner-hierarchical-clinical-reasoning-for-ultrasound-vision-language-mode-64a292dcc7450c31Pharma Surgeen2026-08-03T00:00:00.000ZSonoReasoner: Hierarchical Clinical Reasoning for Ultrasound Vision-Language Modelshttps://www.pharmaradar360.com/article/longitudinal-changes-in-intracranial-eeg-spectral-power-and-phase-locking-value-b327487905a59b1fPharma Surgeen2026-08-03T00:00:00.000ZLongitudinal Changes in Intracranial EEG Spectral Power and Phase-Locking Value During Responsive Neurostimulation Therapy in Drug-Resistant Epilepsyhttps://www.pharmaradar360.com/article/tet2-downregulation-limits-oxidative-stress-induced-cytotoxicity-of-high-dose-as-2ab8b246c7f2d57dPharma Surgeen2026-08-03T00:00:00.000ZTET2 downregulation limits oxidative stress-induced cytotoxicity of high dose ascorbate in dabrafenib-resistant melanoma cellshttps://www.pharmaradar360.com/article/changes-in-bio-psycho-social-aspects-of-male-aging-a-comparative-study-of-hospit-9f83e0b9214c06dcPharma Surgeen2026-08-03T00:00:00.000ZChanges in bio-psycho-social aspects of male aging: A comparative study of hospitalized patients (2013–2023)https://www.pharmaradar360.com/article/clinical-significance-and-outcomes-of-left-sided-gallbladder-for-cholecystectomy-9992ae7de198f1afPharma Surgeen2026-08-03T00:00:00.000ZClinical significance and outcomes of left-sided gallbladder for cholecystectomy: A retrospective cohort study based on 12-year single-center experiencehttps://www.pharmaradar360.com/article/bridging-theory-and-practice-assessing-the-benefits-and-challenges-of-early-clin-1f312860714b2973Pharma Surgeen2026-08-03T00:00:00.000ZBridging Theory and Practice: Assessing the Benefits and Challenges of Early Clinical Exposure in Dental Educationhttps://www.pharmaradar360.com/article/an-exploratory-patient-specific-finite-element-study-of-temporomandibular-joint-5ed954182bca5eeePharma Surgeen2026-08-03T00:00:00.000ZAn exploratory patient-specific finite element study of temporomandibular joint stress distribution following mandibular setback surgery in two distinct clinical scenarioshttps://www.pharmaradar360.com/article/the-relationship-between-in-socket-mechanics-and-patient-reported-comfort-and-fu-b32d62866ca2414aPharma Surgeen2026-08-03T00:00:00.000ZThe relationship between in-socket mechanics and patient-reported comfort and function, a randomized crossover trialhttps://www.pharmaradar360.com/article/effect-of-motivational-interviews-and-peer-education-on-adherence-to-pre-exposur-e4d2f221fa0d3026Pharma Surgeen2026-08-03T00:00:00.000ZEffect of motivational interviews and peer education on adherence to pre-exposure prophylaxis among key populations in Kisangani: a randomized clinical trialhttps://www.pharmaradar360.com/article/diabetic-and-er-stressed-pancreatic-islet-cells-are-in-need-of-some-jnk-removal-488e86bf86899913Pharma Surgeen2026-08-03T00:00:00.000ZDiabetic and ER-stressed pancreatic islet β cells are in need of some JNK removalhttps://www.pharmaradar360.com/article/corrigendum-to-super-enhancer-driven-efna1-fuels-tumor-progression-in-cervical-c-b79bd4f3f0dfe596Pharma Surgeen2026-08-03T00:00:00.000ZCorrigendum to Super-enhancer–driven EFNA1 fuels tumor progression in cervical cancer via the FOSL2-Src/AKT/STAT3 axishttps://www.pharmaradar360.com/article/lymphatic-therapies-open-the-valve-in-marfan-syndrome-232d217917433c28Pharma Surgeen2026-08-03T00:00:00.000ZLymphatic therapies open the valve in Marfan syndromehttps://www.pharmaradar360.com/article/good-cop-bad-cop-rethinking-the-roles-of-cardiac-macrophages-in-injury-8419ee3101178e2fPharma Surgeen2026-08-03T00:00:00.000ZGood cop, bad cop? Rethinking the roles of cardiac macrophages in injuryhttps://www.pharmaradar360.com/article/lingo1-targeted-antibody-drug-conjugates-improve-efficacy-and-tolerability-of-an-b496d4d547d751e4Pharma Surgeen2026-08-03T00:00:00.000ZLINGO1-targeted antibody-drug conjugates improve efficacy and tolerability of antineoplastic therapies in Ewing sarcoma modelshttps://www.pharmaradar360.com/article/supplemental-table-1-from-simvastatin-treatment-in-patients-with-liver-cirrhosis-c4e2eb5660dd2ce2Pharma Surgeen2026-08-03T00:00:00.000ZSupplemental Table 1 from Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levelshttps://www.pharmaradar360.com/article/data-from-first-in-human-trial-of-encapsulated-cells-constitutively-expressing-l-480edefd769258c2Pharma Surgeen2026-08-03T00:00:00.000ZData from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/figure-4-from-benralizumab-for-eosinophil-related-cutaneous-adverse-events-of-an-89cce52119eac6eePharma Surgeen2026-08-03T00:00:00.000ZFigure 4 from Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trialhttps://www.pharmaradar360.com/article/table-2-from-benralizumab-for-eosinophil-related-cutaneous-adverse-events-of-ant-38f212222b315cb6Pharma Surgeen2026-08-03T00:00:00.000ZTable 2 from Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trialhttps://www.pharmaradar360.com/article/supplementary-data-2-from-first-in-human-trial-of-encapsulated-cells-constitutiv-756670e953f8a872Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Data 2 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/supplementary-figure-s3-from-first-in-human-trial-of-encapsulated-cells-constitu-7ff9191610bd8292Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Figure S3 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/supplementary-figure-s5-from-first-in-human-trial-of-encapsulated-cells-constitu-be076a979de4601ePharma Surgeen2026-08-03T00:00:00.000ZSupplementary Figure S5 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/supplementary-figure-s7-from-first-in-human-trial-of-encapsulated-cells-constitu-69a0d19dfb1d8139Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Figure S7 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/supplementary-tables-1-10-from-first-in-human-trial-of-encapsulated-cells-consti-dce05d42a1f18399Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Tables 1-10 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinomahttps://www.pharmaradar360.com/article/supplementary-figure-s10-from-transcriptomic-insights-into-lobular-breast-cancer-567a228b6905e7acPharma Surgeen2026-08-03T00:00:00.000ZSupplementary Figure S10 from Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trialhttps://www.pharmaradar360.com/article/supplementary-data-1-from-the-phase-ib-impact-trial-of-intramuscular-personalize-f0b85f4c0553a235Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Data 1 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinomahttps://www.pharmaradar360.com/article/supplementary-data-2-from-the-phase-ib-impact-trial-of-intramuscular-personalize-679f3331a787eff8Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Data 2 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinomahttps://www.pharmaradar360.com/article/supplementary-data-4-from-the-phase-ib-impact-trial-of-intramuscular-personalize-ffc0ccd9d47ddd52Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Data 4 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinomahttps://www.pharmaradar360.com/article/supplementary-figures-s1-s19-from-phenotypic-and-functional-characteristics-of-c-83e9d92d463153c6Pharma Surgeen2026-08-03T00:00:00.000ZSupplementary Figures S1-S19 from Phenotypic and Functional Characteristics of CD8<sup>+</sup> T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanomahttps://www.pharmaradar360.com/article/supplementary-table-4-from-phase-i-trial-of-ipatasertib-plus-atezolizumab-enhanc-f3ed3ccb0ff9a4fePharma Surgeen2026-08-03T00:00:00.000ZSupplementary Table 4 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastomahttps://www.pharmaradar360.com/article/supplementary-table-s1-from-nivolumab-and-ipilimumab-combination-treatment-in-pa-8fb59282f5deb77fPharma Surgeen2026-08-03T00:00:00.000ZSupplementary Table S1 from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trialhttps://www.pharmaradar360.com/article/variables-associated-with-prescription-opioid-misuse-in-individuals-with-chronic-3449e9e13547da73Pharma Surgeen2026-08-03T00:00:00.000ZVariables Associated with Prescription Opioid Misuse in Individuals with Chronic Noncancer Painhttps://www.pharmaradar360.com/article/integrated-clinical-genetic-pathological-analysis-expands-the-phenotypic-and-mol-365b75d65b06b3fbPharma Surgeen2026-08-03T00:00:00.000ZIntegrated Clinical–Genetic–Pathological Analysis Expands the Phenotypic and Molecular Spectrum of PPNAD Across Carney Complex and Isolated Formshttps://www.pharmaradar360.com/article/profiling-the-pattern-of-medication-use-during-pregnancy-an-international-scopin-a44a6d2de5a98f04Pharma Surgeen2026-08-03T00:00:00.000ZProfiling the pattern of medication use during pregnancy: an international scoping review of observational studieshttps://www.pharmaradar360.com/article/cancer-drug-response-and-resistance-molecular-mechanisms-and-combating-strategie-2523ffad42ef6013Pharma Surgeen2026-08-03T00:00:00.000ZCancer drug response and resistance: molecular mechanisms and combating strategieshttps://www.pharmaradar360.com/article/impact-of-3-day-turmeric-supplementation-on-fasting-and-postprandial-lps-and-chy-843b3b6e5a6c9038Pharma Surgeen2026-08-03T00:00:00.000ZImpact of 3-day turmeric supplementation on fasting and postprandial LPS and chylomicron-related markers in patients with IBS: A randomized crossover trial.https://www.pharmaradar360.com/article/clinical-outcomes-after-week-12-response-guided-secukinumab-discontinuation-in-p-5ed5a159aa14b4acPharma Surgeen2026-08-03T00:00:00.000ZClinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Studyhttps://www.pharmaradar360.com/article/isoquercitrin-suppresses-neuronal-ferroptosis-in-ischemic-stroke-via-sirt1-media-87745ae7ed2d15e7Pharma Surgeen2026-08-03T00:00:00.000ZIsoquercitrin suppresses neuronal ferroptosis in ischemic stroke via SIRT1-mediated deacetylation of H3K9 at the RBM15 promoterhttps://www.pharmaradar360.com/article/novel-fast-dissolving-microneedle-patch-for-transdermal-delivery-of-granisetron-0a7b31c54a0144b6Pharma Surgeen2026-08-03T00:00:00.000ZNovel Fast Dissolving Microneedle Patch for Transdermal Delivery of Granisetron; Optimization, In-Vitro and Ex-Vivo Evaluationhttps://www.pharmaradar360.com/article/cas12a-crrna-recognition-catalyzed-triple-self-priming-cascade-amplification-str-52feae37e9f45103Pharma Surgeen2026-08-03T00:00:00.000ZCas12a/crRNA Recognition Catalyzed Triple Self-Priming Cascade Amplification Strategy for Sensitive and Reliable Drug Resistance Gene Analysishttps://www.pharmaradar360.com/article/integrative-molecular-epidemiology-of-sporothrix-in-latin-america-reveals-calmod-e0239235e8f28051Pharma Surgeen2026-08-03T00:00:00.000ZIntegrative molecular epidemiology of Sporothrix in Latin America reveals calmodulin genotypes associated with host, clinical form and geographic distributionhttps://www.pharmaradar360.com/article/early-effects-of-communities-that-care-on-system-transformation-a-non-randomized-c41024c33f812977Pharma Surgeen2026-08-03T00:00:00.000ZEarly Effects of Communities That Care on System Transformation: a Non-randomized Community Trial in Germanyhttps://www.pharmaradar360.com/article/applicability-and-reliability-of-the-iddsi-functional-diet-scale-iddsi-fds-in-cl-2e0b4d70dd6e047dPharma Surgeen2026-08-03T00:00:00.000ZApplicability and reliability of the IDDSI functional diet scale (IDDSI-FDS) in clinical reports of patients with oropharyngeal dysphagiahttps://www.pharmaradar360.com/article/application-of-multi-technique-integration-in-the-prenatal-diagnosis-of-mosaicis-0fda1f054a0222c1Pharma Surgeen2026-08-03T00:00:00.000ZApplication of multi-technique integration in the prenatal diagnosis of mosaicism derived from an ICSI blastocyst: a diagnostic approach and clinical implicationshttps://www.pharmaradar360.com/article/spiradenocarcinoma-a-systematic-review-of-clinical-features-diagnosis-and-highli-ebd277c581ed8b15Pharma Surgeen2026-08-03T00:00:00.000ZSpiradenocarcinoma: a systematic review of clinical features, diagnosis, and highlighting surgical management of a rare malignant cutaneous adnexal tumorhttps://www.pharmaradar360.com/article/introduction-to-trial-level-subgroup-analysis-a-tutorial-b642fedf37724c88Pharma Surgeen2026-08-03T00:00:00.000ZIntroduction to Trial‐Level Subgroup Analysis: A Tutorialhttps://www.pharmaradar360.com/article/clinical-heterogeneity-and-long-term-outcomes-of-pediatric-gastrointestinal-stro-9ba39789e48b4e7fPharma Surgeen2026-08-03T00:00:00.000ZClinical Heterogeneity and Long‐Term Outcomes of Pediatric Gastrointestinal Stromal Tumors: A Series of Four Patients Highlighting SDH‐Deficient and SDH‐Intact Subtypeshttps://www.pharmaradar360.com/article/bukwang-pharmaceutical-ramps-up-otc-push-with-taceknol-tabexgel-and-sinsin-distr-0b8207037ccdc6e6Pharma Surgeen2026-08-02T23:46:48.000ZBukwang Pharmaceutical ramps up OTC push with Taceknol, Tabexgel and Sinsin distribution tie-uphttps://www.pharmaradar360.com/article/weekly-recap-ha1406-phase-iii-success-and-cspc-innovation-h1-profit-13eaf2741e16e90ePharma Surgeen2026-08-02T23:13:36.000ZWeekly Recap: HA1406 Phase III success and CSPC Innovation H1 profithttps://www.pharmaradar360.com/article/early-surgery-for-bacterial-eye-infection-offers-hope-to-patients-study-f70b2d29c42a590ePharma Surgeen2026-08-02T23:00:04.000ZEarly surgery for bacterial eye infection offers hope to patients: Studyhttps://www.pharmaradar360.com/article/late-model-analytical-and-pharmaceutical-lab-equipment-on-the-market-38ea7d08cd9191efPharma Surgeen2026-08-02T22:46:40.000ZLate-model analytical and pharmaceutical lab equipment on the markethttps://www.pharmaradar360.com/article/an-ode-to-remembrance-on-prescribed-harm-day-oped-d4cee4c83e5d0910Pharma Surgeen2026-08-02T22:27:02.000ZAn Ode To Remembrance On Prescribed Harm Day – OpEdhttps://www.pharmaradar360.com/article/weekly-roundup-on-the-cannabis-sector-psychedelic-sector-41504b84654ae4d9Pharma Surgeen2026-08-02T22:26:28.000ZWeekly Roundup on the Cannabis Sector & Psychedelic Sectorhttps://www.pharmaradar360.com/article/undiscovered-gems-in-asia-featuring-3-promising-small-caps-with-strong-fundament-079891dd34ea04eaPharma Surgeen2026-08-02T22:16:56.000ZUndiscovered Gems In Asia Featuring 3 Promising Small Caps With Strong Fundamentalshttps://www.pharmaradar360.com/article/autism-drug-fails-again-but-sk-biopharm-nature-cell-press-on-01b271032b11aa8ePharma Surgeen2026-08-02T22:01:05.000ZAutism Drug Fails Again, But SK Biopharm, Nature Cell Press Onhttps://www.pharmaradar360.com/article/otlk-stock-jumps-overnight-after-fda-approval-of-wet-amd-drug-analysts-see-nearl-20316cef867e1f53Pharma Surgeen2026-08-02T21:41:14.000ZOTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upsidehttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-sunflower-pharmaceutical-group-co-ltd-cla-046e07be60c949e4Pharma Surgeen2026-08-02T21:36:05.000ZEnterprise value to revenue forward of Sunflower Pharmaceutical Group Co., Ltd. Class A – SZSE:002737https://www.pharmaradar360.com/article/big-pharma-and-the-over-medication-of-high-blood-pressure-e2311639d0646481Pharma Surgeen2026-08-02T21:17:08.000ZBig Pharma, and the Over-Medication of High Blood Pressurehttps://www.pharmaradar360.com/article/korea-overhauls-generic-drug-prices-industry-urges-predictable-pro-innovation-po-d657d39d41e4edcbPharma Surgeen2026-08-02T21:01:00.000ZKorea overhauls generic drug prices, industry urges predictable pro‑innovation policy - CHOSUNBIZhttps://www.pharmaradar360.com/article/novo-nordisk-s-failed-heart-drug-trial-leaves-little-room-for-error-in-wednesday-758b14bf36328e3ePharma Surgeen2026-08-02T20:20:53.000ZNovo Nordisk's Failed Heart Drug Trial Leaves Little Room for Error in Wednesday's Earnings Reporthttps://www.pharmaradar360.com/article/why-billionaire-stanley-druckenmiller-and-wall-street-analysts-love-this-biotech-2f72f04af88fd4e5Pharma Surgeen2026-08-02T20:05:00.000ZWhy Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stockhttps://www.pharmaradar360.com/article/astrazeneca-in-talks-with-bristol-myers-squibb-on-400-billion-megadeal-ft-report-fcb552558f1b3608Pharma Surgeen2026-08-02T20:00:18.000ZAstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reportshttps://www.pharmaradar360.com/article/chantix-side-effects-erectile-dysfunction-view-4wwm8hjtr-bb46501854a8dfc6Pharma Surgeen2026-08-02T19:25:00.000Z# Chantix Side Effects Erectile Dysfunction - View 4wwM8hJTRhttps://www.pharmaradar360.com/article/abbv-stock-gains-on-winning-fda-approval-for-rare-blood-cancer-drug-1cabfd1aed67f747Pharma Surgeen2026-08-02T19:23:00.000ZABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drughttps://www.pharmaradar360.com/article/on-peptides-fda-staff-scientists-at-odds-with-advisory-panel-e371441029a7c794Pharma Surgeen2026-08-02T19:21:39.000ZOn Peptides, FDA Staff Scientists At Odds With Advisory Panelhttps://www.pharmaradar360.com/article/new-erectile-dysfunction-drug-view-zue1hs70b-7beaeda772e40520Pharma Surgeen2026-08-02T18:46:19.000ZNew Erectile Dysfunction Drug - View zue1hS70bhttps://www.pharmaradar360.com/article/erectile-dysfunction-cream-fda-approval-your-practical-guide-to-otc-options-ieyw-8479106bdee07b15Pharma Surgeen2026-08-02T18:45:06.000Z# Erectile Dysfunction Cream FDA Approval: Your Practical Guide to OTC Options *IEywe3Dba*https://www.pharmaradar360.com/article/kelun-biotech-s-trop2-adc-sac-tmt-advances-toward-first-line-tnbc-approval-in-ch-265d1cbf808675f8Pharma Surgeen2026-08-02T18:34:30.000ZKelun-Biotech's TROP2 ADC sac-TMT Advances Toward First-Line TNBC Approval in Chinahttps://www.pharmaradar360.com/article/fda-approved-erectile-dysfunction-medication-evidence-based-options-for-men-s-we-ef429f5fd67bb288Pharma Surgeen2026-08-02T17:51:37.000ZFDA Approved Erectile Dysfunction Medication: Evidence-Based Options for Men's Wellness *E7drVvNoL*https://www.pharmaradar360.com/article/why-teva-pharmaceutical-stock-surged-this-week-f2d039f566066d39Pharma Surgeen2026-08-02T17:44:00.000ZWhy Teva Pharmaceutical Stock Surged This Weekhttps://www.pharmaradar360.com/article/price-to-book-forward-of-aurisco-pharmaceutical-co-ltd-class-a-sse-605116-49ce62c1d648157aPharma Surgeen2026-08-02T17:43:31.000ZPrice to book forward of Aurisco Pharmaceutical Co. Ltd. Class A – SSE:605116https://www.pharmaradar360.com/article/topical-erectile-dysfunction-gel-fast-acting-options-that-actually-fit-real-life-a77161389d7239bePharma Surgeen2026-08-02T17:11:10.000Z# Topical Erectile Dysfunction Gel: Fast-Acting Options That Actually Fit Real Life *dW7CLxni8*https://www.pharmaradar360.com/article/why-teva-pharmaceutical-stock-surged-this-week-556b237344366bd3Pharma Surgeen2026-08-02T17:04:00.000ZWhy Teva Pharmaceutical Stock Surged This Weekhttps://www.pharmaradar360.com/article/symptoms-improved-within-first-week-fda-approves-new-adhd-drug-for-children-adul-e789c5b5ffacfaeePharma Surgeen2026-08-02T16:49:44.000ZSymptoms improved within first week: FDA approves new ADHD drug for children, adultshttps://www.pharmaradar360.com/article/etfs-investing-in-jinling-pharmaceutical-co-ltd-class-a-stocks-b32094a305a44872Pharma Surgeen2026-08-02T16:35:35.000ZETFs Investing in Jinling Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/erectile-dysfunction-medication-free-samples-what-they-are-where-to-get-them-and-32613357943ed80ePharma Surgeen2026-08-02T15:51:05.000Z# Erectile Dysfunction Medication Free Samples: What They Are, Where to Get Them, and How to Choose Wisely in 2026 *L8F800FYy*https://www.pharmaradar360.com/article/egyptian-drug-authority-studies-new-flexible-pricing-system-as-pharmaceutical-co-4cca9c56552e787ePharma Surgeen2026-08-02T15:17:08.000ZEgyptian Drug Authority studies new flexible pricing system as pharmaceutical companies push for increaseshttps://www.pharmaradar360.com/article/vktx-stock-lags-glp-1-peers-in-july-but-viking-ceo-says-its-obesity-drug-could-o-55e28e0768872cf0Pharma Surgeen2026-08-02T14:55:31.000ZVKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’thttps://www.pharmaradar360.com/article/dftx-vs-cmps-which-stock-has-more-upside-from-trump-s-new-psychedelic-therapy-pu-ef64dcf5e3960581Pharma Surgeen2026-08-02T14:51:19.000ZDFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?https://www.pharmaradar360.com/article/ukhsa-updates-heat-health-alerts-across-england-ed2386aedcea3cbcPharma Surgeen2026-08-02T14:44:11.000ZUKHSA updates heat health alerts across Englandhttps://www.pharmaradar360.com/article/heat-sealing-pharmaceutical-films-market-growth-to-2035-driven-by-biologics-barr-0b5a3648386df724Pharma Surgeen2026-08-02T14:41:12.000ZHeat-Sealing Pharmaceutical Films Market Growth to 2035 Driven by Biologics Barrier Needs - News and Statisticshttps://www.pharmaradar360.com/article/fda-advisory-committee-backs-rp1-for-advanced-melanoma-bd506dd450d509a0Pharma Surgeen2026-08-02T14:37:01.000ZFDA Advisory Committee Backs RP1 for Advanced Melanomahttps://www.pharmaradar360.com/article/fda-approved-otc-testosterone-booster-view-kvn8909yx-a6dc51915b5bf0abPharma Surgeen2026-08-02T14:27:38.000Z# FDA Approved OTC Testosterone Booster - View KVn8909yxhttps://www.pharmaradar360.com/article/eroxon-erectile-dysfunction-gel-effectiveness-clinical-trial-results-view-zfbirs-7f59663ddb7f46a6Pharma Surgeen2026-08-02T14:16:43.000ZEroxon Erectile Dysfunction Gel Effectiveness Clinical Trial Results - View zfBiRSPH7https://www.pharmaradar360.com/article/food-safety-yes-public-shaming-no-hospitality-industry-s-appeal-to-fda-1e6d78c14618a451Pharma Surgeen2026-08-02T14:16:23.000ZFood safety yes, public shaming no: Hospitality industry's appeal to FDAhttps://www.pharmaradar360.com/article/new-chemotherapy-free-immunotherapy-combination-for-follicular-lymphoma-listed-o-d405f28dce8a6514Pharma Surgeen2026-08-02T14:16:10.000ZNew Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBShttps://www.pharmaradar360.com/article/dear-teva-pharmaceutical-stock-fans-mark-your-calendars-for-september-14-72020913f2a3f91cPharma Surgeen2026-08-02T14:14:02.000ZDear Teva Pharmaceutical Stock Fans, Mark Your Calendars for September 14https://www.pharmaradar360.com/article/sichuan-kelun-biotech-biopharmaceutical-sehk-6990-following-new-tnbc-filing-has-a9eae67b77e31e6aPharma Surgeen2026-08-02T14:07:58.000ZSichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Following New TNBC Filing Has Valuation Back In Focushttps://www.pharmaradar360.com/article/this-mad-scientist-built-india-s-first-pharmaceutical-company-made-major-discove-cc17bd33ba1c5925Pharma Surgeen2026-08-02T14:02:13.000ZTHIS ‘mad scientist’ built India’s first pharmaceutical company, made major discoveries in Chemistry, donated entire fortune to charity, his name was…https://www.pharmaradar360.com/article/access-to-care-and-drug-prices-recent-department-of-health-and-human-services-gu-da53f53bf784b489Pharma Surgeen2026-08-02T14:00:00.000ZAccess to Care and Drug Prices: Recent Department of Health and Human Services Guidancehttps://www.pharmaradar360.com/article/sfda-approves-registration-of-foundayo-for-weight-management-87639de337bff9edPharma Surgeen2026-08-02T13:51:42.000ZSFDA Approves Registration of Foundayo for Weight Managementhttps://www.pharmaradar360.com/article/can-ketamine-cause-erectile-dysfunction-view-rgcntyqym-150ee49c173935d6Pharma Surgeen2026-08-02T13:13:49.000Z# Can Ketamine Cause Erectile Dysfunction - View RGcNtyQYmhttps://www.pharmaradar360.com/article/handa-oncology-receives-fda-tentative-approval-for-omcazio-cabozantinib-capsules-6246af764b75ab74Pharma Surgeen2026-08-02T13:07:07.000ZHanda Oncology Receives FDA Tentative Approval for OMCAZIO (cabozantinib) Capsuleshttps://www.pharmaradar360.com/article/study-hiv-injectable-drug-offers-pregnant-lactating-mothers-100-protection-fd8a9e947cd3f2f2Pharma Surgeen2026-08-02T13:00:59.000ZSTUDY: HIV injectable drug offers pregnant, lactating mothers 100% protectionhttps://www.pharmaradar360.com/article/union-minister-rajiv-ranjan-singh-stresses-research-in-pharma-and-biotech-sector-6900c5ef1cdf19fcPharma Surgeen2026-08-02T12:57:41.000ZUnion Minister Rajiv Ranjan Singh stresses research in pharma and biotech sectors | Akashvani Newshttps://www.pharmaradar360.com/article/prescription-hope-reviews-view-hvzvrkwn2-06d73269535a287cPharma Surgeen2026-08-02T12:31:14.000Z# Prescription Hope Reviews - View hvzVrKwn2https://www.pharmaradar360.com/article/senate-panel-to-examine-biotech-s-role-in-u-s-health-resilience-b12f7b7387463c14Pharma Surgeen2026-08-02T12:28:52.000ZSenate Panel To Examine Biotech's Role in U.S. Health Resiliencehttps://www.pharmaradar360.com/article/aids2026-daily-pill-monthly-pill-six-monthly-jab-why-choice-matters-83f83fdb429a4875Pharma Surgeen2026-08-02T12:00:41.000Z#Aids2026: Daily pill. Monthly pill. Six-monthly jab. Why choice mattershttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhejiang-shouxiangu-pharmaceutical-holding-c-656387bdd0f2cc33Pharma Surgeen2026-08-02T11:55:25.000ZEnterprise value to EBIT forward of Zhejiang Shouxiangu Pharmaceutical Holding Co. Ltd. Class A – SSE:603896https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-shanxi-c-y-pharmaceutical-group-co-ltd-cla-8d2bbfd0953994dbPharma Surgeen2026-08-02T11:08:12.000ZEnterprise value to EBITDA forward of Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A – SZSE:300254https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-shanxi-c-y-pharmaceutical-group-co-ltd-cl-1eb186da4bafeda5Pharma Surgeen2026-08-02T11:02:26.000ZEnterprise value to revenue forward of Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A – SZSE:300254https://www.pharmaradar360.com/article/5-biotech-stocks-that-delivered-big-gains-key-catalysts-ahead-for-qure-cdna-adpt-09bb6aed56c386c1Pharma Surgeen2026-08-02T10:54:00.000Z5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLXhttps://www.pharmaradar360.com/article/hoth-s-pivot-from-biotech-to-space-tech-sparks-massive-rally-in-stock-retail-und-fea1a8d486dec34bPharma Surgeen2026-08-02T10:48:49.000ZHOTH’s Pivot From Biotech To Space Tech Sparks Massive Rally In Stock – Retail Underlines Importance Of Securing Fresh Dealshttps://www.pharmaradar360.com/article/kelun-pharmaceutical-002422-sz-multiple-drug-products-provisionally-awarded-in-t-ec5ed1e2d068e3bdPharma Surgeen2026-08-02T10:23:12.000ZKelun Pharmaceutical (002422.SZ): Multiple drug products provisionally awarded in the 12th batch of national centralized drug procurementhttps://www.pharmaradar360.com/article/my-job-is-to-ensure-safe-food-fda-chief-warns-of-wider-crackdown-after-restauran-84c9f26061c96b9ePharma Surgeen2026-08-02T09:47:37.000Z'My job is to ensure safe food': FDA chief warns of wider crackdown after restaurant hygiene inspectionshttps://www.pharmaradar360.com/article/cm-sawant-calls-for-public-support-to-build-a-drug-free-goa-8e410580b44e3397Pharma Surgeen2026-08-02T09:33:00.000ZCM Sawant Calls For Public Support To Build A Drug-Free Goahttps://www.pharmaradar360.com/article/etfs-investing-in-zhejiang-starry-pharmaceutical-co-ltd-class-a-stocks-6efc76bc1b8fbb75Pharma Surgeen2026-08-02T09:24:49.000ZETFs Investing in Zhejiang Starry Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/a-who-was-taking-a-treatment-for-dyslipidemia-lipidemia-recently-saw-that-the-na-4d8db33b79dcc375Pharma Surgeen2026-08-02T08:47:41.000ZA, who was taking a treatment for dyslipidemia (lipidemia), recently saw that the name of the drug c..https://www.pharmaradar360.com/article/the-pharmaceutical-industry-is-expanding-retro-marketing-with-the-history-of-lon-72ff8e3f7ad82859Pharma Surgeen2026-08-02T08:44:50.000ZThe pharmaceutical industry is expanding "retro marketing" with the history of long-lived brands and..https://www.pharmaradar360.com/article/maharashtra-fda-chief-vows-stricter-action-against-hygiene-medicine-norm-violati-a604a85fa4139346Pharma Surgeen2026-08-02T08:39:16.000ZMaharashtra FDA chief vows stricter action against hygiene, medicine norm violationshttps://www.pharmaradar360.com/article/amgen-amgn-partners-with-mrbeast-to-fund-pediatric-cancer-research-and-reach-500-2d74ff7aa3cf822fPharma Surgeen2026-08-02T08:15:46.000ZAmgen (AMGN) Partners With MrBeast To Fund Pediatric Cancer Research And Reach 500 Million Subscribershttps://www.pharmaradar360.com/article/why-is-maharashtra-fda-targeting-restaurants-commissioner-tukaram-mundhe-explain-66ab71c1d13f28d3Pharma Surgeen2026-08-02T08:10:21.000ZWhy Is Maharashtra FDA Targeting Restaurants? Commissioner Tukaram Mundhe Explainshttps://www.pharmaradar360.com/article/tukaram-mundhe-s-big-warning-to-pharmacists-amid-rising-antimicrobial-resistance-59e8caa93b178513Pharma Surgeen2026-08-02T07:55:53.000ZTukaram Mundhe's Big Warning To Pharmacists Amid Rising Antimicrobial Resistancehttps://www.pharmaradar360.com/article/ppb-chair-munyu-calls-for-ethical-practice-as-kenya-advances-pharmaceutical-refo-d114ff4715d387a6Pharma Surgeen2026-08-02T07:53:00.000ZPPB chair Munyu calls for ethical practice as Kenya advances pharmaceutical reformshttps://www.pharmaradar360.com/article/dr-reddy-s-gets-usfda-nod-for-rituximab-biosimilar-89b7034eadc010f7Pharma Surgeen2026-08-02T07:34:35.000ZDr. Reddy's Gets USFDA Nod for Rituximab Biosimilarhttps://www.pharmaradar360.com/article/the-clinical-trial-that-asks-whether-your-current-treatment-should-exist-32b3fdfc0f99c6daPharma Surgeen2026-08-02T07:28:08.000ZThe Clinical Trial That Asks Whether Your Current Treatment Should Existhttps://www.pharmaradar360.com/article/why-only-private-eateries-after-bombay-hc-s-query-fda-team-reaches-canteens-at-h-3087d0a2e68077dfPharma Surgeen2026-08-02T07:25:00.000Z'Why only private eateries?': After Bombay HC's query, FDA team reaches canteens at HChttps://www.pharmaradar360.com/article/ntla-stock-surges-35-overnight-retail-mood-peaks-ahead-of-first-ever-phase-3-rea-d5beb93535a18e5ePharma Surgeen2026-08-02T07:21:30.000ZNTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapyhttps://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875Pharma Surgeen2026-08-02T07:07:40.000ZSLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upsidehttps://www.pharmaradar360.com/article/case-biotech-research-sowing-seeds-for-jamaica-s-future-660a5137ad7be6a5Pharma Surgeen2026-08-02T06:04:11.000ZCASE biotech research sowing seeds for Jamaica’s futurehttps://www.pharmaradar360.com/article/price-to-sales-forward-of-protect-pharmaceutical-corp-otc-prtt-def4c2ab610055fdPharma Surgeen2026-08-02T05:51:54.000ZPrice to sales forward of Protect Pharmaceutical Corp – OTC:PRTThttps://www.pharmaradar360.com/article/concord-biotech-q1-fy27-strong-growth-marred-by-sequential-decline-and-valuation-9acf88826b7b7460Pharma Surgeen2026-08-02T05:31:26.000ZConcord Biotech Q1 FY27: Strong Growth Marred by Sequential Decline and Valuation Concernshttps://www.pharmaradar360.com/article/matica-bio-zeroes-in-on-bridging-global-biotech-with-korea-795be978ba0a6b14Pharma Surgeen2026-08-02T05:21:08.000ZMatica Bio zeroes in on bridging global biotech with Koreahttps://www.pharmaradar360.com/article/tukaram-mundhe-explains-his-philosophy-as-fda-cracks-down-on-restaurants-my-role-e59e262a9ece9234Pharma Surgeen2026-08-02T05:17:46.000ZTukaram Mundhe Explains His Philosophy As FDA Cracks Down On Restaurants: 'My Role Is To...'https://www.pharmaradar360.com/article/medicamen-biotech-ltd-is-rated-sell-f7b5b6fe4af16e07Pharma Surgeen2026-08-02T05:05:44.000ZMedicamen Biotech Ltd is Rated Sellhttps://www.pharmaradar360.com/article/cramer-this-biotech-stock-could-be-worth-over-100-billion-on-an-fda-approval-bra-124a3cc586a9fa9ePharma Surgeen2026-08-02T05:00:37.000ZCramer: This Biotech Stock Could Be Worth Over $100 Billion On An FDA Approval Braves Standings (7nBNgCwFes)https://www.pharmaradar360.com/article/kathua-biotech-park-to-drive-innovation-jobs-across-j-k-north-india-jitendra-sin-21fcb876fbc77ec6Pharma Surgeen2026-08-02T04:17:16.000ZKathua Biotech Park to drive innovation, jobs across J&K, north India: Jitendra Singhhttps://www.pharmaradar360.com/article/fda-warns-against-soaking-cut-avocado-in-water-4-safe-ways-to-prevent-browning-4fbf37d5e4db912bPharma Surgeen2026-08-02T04:00:51.000ZFDA warns against soaking cut avocado in water - 4 safe ways to prevent browninghttps://www.pharmaradar360.com/article/govt-committed-to-building-globally-competitive-innovation-driven-pharma-sector-7ea9ff6bb1f753d6Pharma Surgeen2026-08-02T03:28:00.000ZGovt committed to building globally competitive, innovation-driven pharma sector: Piyush Goyalhttps://www.pharmaradar360.com/article/piyush-goyal-invites-global-pharma-firms-to-invest-in-india-b5bf561e4e00c67aPharma Surgeen2026-08-02T03:27:53.000ZPiyush Goyal invites global pharma firms to invest in Indiahttps://www.pharmaradar360.com/article/biotech-pro-testosterone-booster-reviews-real-user-insights-for-long-term-metabo-47fba996b9018eb6Pharma Surgeen2026-08-02T03:26:54.000ZBiotech Pro Testosterone Booster Reviews: Real User Insights for Long-Term Metabolic Health *arBxoRmlL*https://www.pharmaradar360.com/article/novo-drug-fails-to-reduce-cardiovascular-risk-in-late-stage-trial-6691cb4fa3a31b3fPharma Surgeen2026-08-02T03:25:25.000ZNovo drug fails to reduce cardiovascular risk in late-stage trialhttps://www.pharmaradar360.com/article/what-is-the-latest-treatment-for-erectile-dysfunction-2023-view-9zawavrxl-61c8f12446c27241Pharma Surgeen2026-08-02T03:02:30.000Zwhat is the latest treatment for erectile dysfunction 2023 - View 9zawaVRXlhttps://www.pharmaradar360.com/article/mounjaro-fda-approval-status-2026-clinical-weight-loss-data-and-doctor-recommend-e05d64b9262d491ePharma Surgeen2026-08-02T02:19:55.000ZMounjaro Fda Approval Status 2026: Clinical Weight Loss Data And Doctor Recommendations [ZkkgCv7lTTq]https://www.pharmaradar360.com/article/michael-explains-exciting-apitegromab-clinical-trial-ufo-files-j8htefim7t-a4b77ac71e3c8ab0Pharma Surgeen2026-08-02T02:12:16.000ZMichael Explains Exciting Apitegromab Clinical Trial Ufo Files (j8HtefIM7t)https://www.pharmaradar360.com/article/etfs-investing-in-samsung-pharmaceutical-co-ltd-stocks-6b3fe25790c69497Pharma Surgeen2026-08-02T01:51:33.000ZETFs Investing in SAMSUNG PHARMACEUTICAL.CO.,Ltd. Stockshttps://www.pharmaradar360.com/article/etfs-investing-in-xizang-weixinkang-pharmaceutical-co-ltd-class-a-stocks-dff793f4d1b9d951Pharma Surgeen2026-08-02T01:50:34.000ZETFs Investing in Xizang Weixinkang Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/glp-1-obesity-drug-news-today-latest-advancements-and-clinical-breakthroughs-gw6-dc471a7fe6be6c3cPharma Surgeen2026-08-02T01:44:39.000ZGlp 1 Obesity Drug News Today: Latest Advancements And Clinical Breakthroughs [gw6cCHEEIHc]https://www.pharmaradar360.com/article/testrovax-testosterone-boosting-compound-90ct-by-novex-biotech-view-dwbsgefpa-6caaa358a8002823Pharma Surgeen2026-08-02T01:07:19.000Z# TestroVax Testosterone Boosting Compound 90ct by Novex Biotech - View dWBSGefPahttps://www.pharmaradar360.com/article/nail-fungus-clinical-trials-what-the-research-really-says-for-long-term-nail-hea-19b4d74c9882d9d5Pharma Surgeen2026-08-02T01:02:49.000ZNail Fungus Clinical Trials: What the Research Really Says for Long-Term Nail Health [B8OIi5vgZ]https://www.pharmaradar360.com/article/the-ultimate-guide-to-finding-the-cheapest-glp-1-without-insurance-costs-compoun-536d665e1e103b5dPharma Surgeen2026-08-02T00:53:59.000ZThe Ultimate Guide To Finding The Cheapest Glp 1 Without Insurance: Costs, Compounded Options, And Safety [MpalSXSTADx]https://www.pharmaradar360.com/article/court-rules-blocking-abortion-pill-site-justified-59667787ca317483Pharma Surgeen2026-08-02T00:53:38.000ZCourt Rules Blocking Abortion Pill Site Justifiedhttps://www.pharmaradar360.com/article/keto-blast-gummies-fda-what-the-regulations-really-mean-for-this-supplement-v3jg-f4f76269c4465f93Pharma Surgeen2026-08-02T00:49:31.000ZKeto Blast Gummies Fda: What The Regulations Really Mean For This Supplement [V3JGqoPlI6c]https://www.pharmaradar360.com/article/tension-has-been-running-high-in-the-global-pharmaceutical-industry-two-companie-d151e30148a1c80dPharma Surgeen2026-08-02T00:30:35.000ZTension has been running high in the global pharmaceutical industry. Two companies that dominate the..https://www.pharmaradar360.com/article/etfs-investing-in-nanjing-king-friend-biochemical-pharmaceutical-co-ltd-class-a-f38663ad4a773a64Pharma Surgeen2026-08-02T00:30:32.000ZETFs Investing in Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/genbio-inc-to-participate-in-the-2026-asia-bio-partnering-forum-in-singapore-36ff03d0ccb520f5Pharma Surgeen2026-08-02T00:01:28.000ZGenBio Inc. to Participate in the 2026 Asia Bio Partnering Forum in Singaporehttps://www.pharmaradar360.com/article/population-pharmacokinetic-comparability-of-ct-p16-versus-eu-avastin-lt-sup-gt-l-44c0a1c83d19678ePharma Surgeen2026-08-02T00:00:00.000ZPopulation Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin<sup>®</sup> and US-Avastin<sup>®</sup> in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer.https://www.pharmaradar360.com/article/work-related-quality-of-life-and-its-demographic-correlates-among-nurse-educator-345248ec12d07e41Pharma Surgeen2026-08-02T00:00:00.000ZWork-Related Quality of Life and Its Demographic Correlates among Nurse Educators and Clinical Instructors in Philippine Higher Education Institutions: A Descriptive-Correlational Studyhttps://www.pharmaradar360.com/article/the-relationship-between-legal-instructions-and-factual-circumstances-in-a-jury-eca40a6464a4bedfPharma Surgeen2026-08-02T00:00:00.000ZTHE RELATIONSHIP BETWEEN LEGAL INSTRUCTIONS AND FACTUAL CIRCUMSTANCES IN A JURY TRIALhttps://www.pharmaradar360.com/article/clinical-and-molecular-study-of-upper-respiratory-tract-infections-caused-by-kle-b31dec8fe4eadd6cPharma Surgeen2026-08-02T00:00:00.000ZCLINICAL AND MOLECULAR STUDY OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY KLEBSIELLA PNEUMONIAE IN CATShttps://www.pharmaradar360.com/article/the-effects-of-combined-periodontal-and-orthodontic-treatment-in-periodontally-c-8daaad2d4417293ePharma Surgeen2026-08-02T00:00:00.000ZThe Effects of Combined Periodontal and Orthodontic Treatment in Periodontally Compromised Adult Patients: A Longitudinal Clinical Studyhttps://www.pharmaradar360.com/article/clinical-approaches-to-non-ordinary-experiences-noes-scoping-review-and-bibliome-e7f1148c3a3e3cd9Pharma Surgeen2026-08-02T00:00:00.000ZClinical Approaches to Non-Ordinary Experiences (NOEs): scoping review and bibliometric analysishttps://www.pharmaradar360.com/article/perceptions-and-practices-of-medical-interns-on-clinical-empathy-3b2f16f191e564b6Pharma Surgeen2026-08-02T00:00:00.000ZPerceptions and Practices of Medical Interns on Clinical Empathyhttps://www.pharmaradar360.com/article/association-of-the-lt-i-gt-t-53-pro72arg-lt-i-gt-polymorphism-with-lymphovascula-59bc4cd9c81c6fa1Pharma Surgeen2026-08-02T00:00:00.000ZAssociation of the <i>TР53 Pro72Arg</i> polymorphism with lymphovascular space invasion and survival in cervical cancerhttps://www.pharmaradar360.com/article/improvement-in-lipid-profile-and-sex-hormones-with-oleoylethanolamide-supplement-cb68a165324e2dabPharma Surgeen2026-08-02T00:00:00.000ZImprovement in Lipid Profile and Sex Hormones with Oleoylethanolamide Supplement in Women with Polycystic Ovary Syndrome: A Clinical Trialhttps://www.pharmaradar360.com/article/the-effect-of-moderate-intensity-crossfit-training-on-serum-vitamin-d-levels-and-1f851af11331ecccPharma Surgeen2026-08-02T00:00:00.000ZThe Effect of Moderate Intensity CrossFit Training on Serum Vitamin D Levels and Anthropometric Measures in Overweight/Obese Adult Women: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/knowledge-awareness-and-attitudes-toward-food-drug-interactions-among-a-sample-o-ae8cd282adeaa6b1Pharma Surgeen2026-08-02T00:00:00.000ZKnowledge, Awareness, and Attitudes toward Food–Drug Interactions among a Sample of the Iraqi Population in Baghdad: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/proximal-type-epithelioid-sarcoma-of-the-vulva-a-case-report-422a2b63e39e609aPharma Surgeen2026-08-02T00:00:00.000ZProximal Type” Epithelioid Sarcoma of the Vulva: A Case Reporthttps://www.pharmaradar360.com/article/functional-urinary-retention-in-children-and-adolescents-acase-report-fd1274ff3667ee9aPharma Surgeen2026-08-02T00:00:00.000ZFunctional Urinary Retention in Children and Adolescents: ACase Reporthttps://www.pharmaradar360.com/article/cholangiocellular-cancer-metastasis-in-the-terminal-ileum-a-case-report-ac0f63a6ac0d1d0dPharma Surgeen2026-08-02T00:00:00.000ZCholangiocellular Cancer Metastasis in the Terminal Ileum: A Case Reporthttps://www.pharmaradar360.com/article/management-of-daunorubicin-extravasation-with-dexrazoxane-in-a-child-47e75ebad289851cPharma Surgeen2026-08-02T00:00:00.000ZManagement of Daunorubicin Extravasation with Dexrazoxane in a Childhttps://www.pharmaradar360.com/article/a-confluence-of-autoimmunity-in-a-male-patient-severe-hypothyroidism-with-massiv-6caab5382092402dPharma Surgeen2026-08-02T00:00:00.000ZA Confluence of Autoimmunity in a Male Patient: Severe Hypothyroidism with Massive Pericardial Effusion, Sjögren’s Syndrome, and Vasculitishttps://www.pharmaradar360.com/article/extra-articular-tibia-vara-deformity-managed-with-kinematic-aligned-total-knee-a-3494ac0f325c97f0Pharma Surgeen2026-08-02T00:00:00.000ZExtra-Articular Tibia Vara Deformity Managed with Kinematic Aligned Total Knee Arthroplasty: A Case Reporthttps://www.pharmaradar360.com/article/percutaneous-endovascular-retrieval-of-an-embolized-chemotherapy-port-a-cath-fra-7e49f83d8e8fe113Pharma Surgeen2026-08-02T00:00:00.000ZPercutaneous Endovascular Retrieval of an Embolized Chemotherapy Port-A-Cath Fragment from the Superior Vena Cava Utilizing a Snare System: A Case Reporthttps://www.pharmaradar360.com/article/post-covid-19-complications-a-trigger-for-the-onset-of-depression-to-treatment-r-e1b2d5d93ef23e35Pharma Surgeen2026-08-02T00:00:00.000ZPost-COVID-19 Complications:A Trigger for the Onset of Depression to Treatment-Resistant Depression: A Case Reporthttps://www.pharmaradar360.com/article/clinical-utility-of-the-tamil-speech-in-noise-test-for-detecting-hidden-hearing-479bc4490a28fa58Pharma Surgeen2026-08-02T00:00:00.000ZClinical Utility of the Tamil Speech-in-Noise Test for Detecting Hidden Hearing Loss in Tinnitus with Normal Audiograms: Insights from Behavioral and Electrophysiological Measureshttps://www.pharmaradar360.com/article/mental-health-nursing-and-clinical-supervision-a-critical-discussion-of-key-issu-ce371292ac68e058Pharma Surgeen2026-08-02T00:00:00.000ZMental health nursing and clinical supervision: a critical discussion of key issues around international policy developmentshttps://www.pharmaradar360.com/article/the-first-72-hours-of-acute-pancreatitis-patterns-of-variability-in-early-clinic-a8efcb8d98e10620Pharma Surgeen2026-08-02T00:00:00.000ZThe first 72 hours of acute pancreatitis: patterns of variability in early clinical decision-makinghttps://www.pharmaradar360.com/article/clinical-determinants-of-neonatal-mortality-at-a-tertiary-hospital-in-a-resource-63eb86811fc72bf0Pharma Surgeen2026-08-02T00:00:00.000ZClinical determinants of neonatal mortality at a tertiary hospital in a resource limited setting: a retrospective cohort studyhttps://www.pharmaradar360.com/article/comparison-of-clinical-characteristics-and-outcomes-of-systemic-lupus-erythemato-431964f9d63c9d49Pharma Surgeen2026-08-02T00:00:00.000ZComparison of Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus-associated Thrombotic Thrombocytopenic Purpura and Idiopathic Thrombotic Thrombocytopenic Purpura: A Single Centre Study from Eastern Indiahttps://www.pharmaradar360.com/article/workplace-violence-in-indonesian-clinical-learning-environments-cultural-and-org-c3e8849246cb6696Pharma Surgeen2026-08-02T00:00:00.000ZWorkplace Violence in Indonesian Clinical Learning Environments: Cultural and Organisational Contexts Shaping Nursing Students' Experienceshttps://www.pharmaradar360.com/article/in-vitro-antiamoebic-activity-of-novel-metronidazole-derivatives-and-silver-nano-09045b171394c5b0Pharma Surgeen2026-08-02T00:00:00.000ZIn vitro antiamoebic activity of novel metronidazole derivatives and silver nanoparticle formulations against clinical isolates of Entamoeba histolyticahttps://www.pharmaradar360.com/article/clinical-and-functional-outcomes-of-bone-defect-reconstruction-using-the-masquel-ba7c88c79a63570aPharma Surgeen2026-08-02T00:00:00.000ZClinical and Functional Outcomes of Bone Defect Reconstruction Using the Masquelet Technique: Experience with Rare Talus and Metatarsal Caseshttps://www.pharmaradar360.com/article/liposomal-bupivacaine-incisional-infiltration-for-postoperative-analgesia-after-f2d1db30bb27f94fPharma Surgeen2026-08-02T00:00:00.000ZLiposomal Bupivacaine Incisional Infiltration for Postoperative Analgesia After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: A Randomized Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/a-radiotherapy-related-fibrosis-gene-signature-based-risk-model-for-predicting-p-b237f07fd4a9ac55Pharma Surgeen2026-08-02T00:00:00.000ZA radiotherapy-related fibrosis gene signature-based risk model for predicting prognosis and immunological features in lung adenocarcinomahttps://www.pharmaradar360.com/article/additional-effects-of-group-training-and-online-exercise-to-a-12-week-online-pac-d5c897d5f6908f3bPharma Surgeen2026-08-02T00:00:00.000ZAdditional effects of group training and online exercise to a 12-week online pacing and education module on health-related quality of life in adult patients with post COVID-19: a randomized controlled trialhttps://www.pharmaradar360.com/article/ai-automation-of-statistical-analysis-plans-in-clinical-trials-7ed23ec41ca67d2aPharma Surgeen2026-08-02T00:00:00.000ZAI Automation of Statistical Analysis Plans in Clinical Trialshttps://www.pharmaradar360.com/article/improving-hospital-process-management-through-process-mining-a-case-study-on-cov-7f4c3050870dc43fPharma Surgeen2026-08-02T00:00:00.000ZImproving Hospital Process Management Through Process Mining: A Case Study on COVID-19 Clinical Pathwayshttps://www.pharmaradar360.com/article/pills-and-perspectives-decoding-stance-on-drug-use-with-the-rxtance-dataset-07e6f2a2ecd03424Pharma Surgeen2026-08-02T00:00:00.000ZPills and Perspectives: Decoding Stance on Drug Use with the Rxtance Datasethttps://www.pharmaradar360.com/article/clinical-impact-of-gleason-pattern-5-on-doublet-versus-triplet-therapy-in-metast-5dca45945af00d31Pharma Surgeen2026-08-02T00:00:00.000ZClinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancerhttps://www.pharmaradar360.com/article/does-retatrutide-cause-erectile-dysfunction-view-ooajqo0si-9bcefed01b8140efPharma Surgeen2026-08-01T23:29:50.000ZDoes Retatrutide Cause Erectile Dysfunction? - View OoaJqO0Si